Hidradenitis Suppurativa (Hurley Stage I-II)
Investigational adjunctive use for Hurley stage I-II hidradenitis suppurativa in quiescent phase between flares.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for hidradenitis suppurativa (HS). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for HS is investigational.
- Welche Evidenz existiert?
- Tier C (investigational). One small case series (n=15) describes improvement in flare frequency in Hurley stage I-II disease, applied only during quiescent intervals. There are no randomized controlled trials. Evidence-based therapy includes topical clindamycin, oral antibiotics (tetracyclines, clindamycin-rifampicin), adalimumab (FDA-approved for moderate-to-severe HS), secukinumab (newly approved), hormonal therapy, and surgical excision (deroofing, wide excision) for refractory disease. Leech application on active draining lesions is dangerous.
- Hauptrisiken
- Dangerous infection spread if leeches are applied on or near actively draining lesions
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness in the axilla, groin, or other intertriginous areas for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection (amplified in HS-prone skin)
- Allergic reaction to leech saliva (uncommon)
- Triggering a new HS flare at the bite site
- Small permanent scars in already scar-prone tissue
- Delay or replacement of evidence-based biologic or antibiotic therapy
- Wer dies nicht in Betracht ziehen sollte
- Patients with any active draining lesion, abscess, or sinus tract
- Patients with Hurley stage III disease (extensive sinus tract formation)
- Patients on immunosuppression with neutropenia (TNF inhibitors, methotrexate)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients with poorly controlled diabetes (higher infection risk)
- Patients who have not been evaluated by dermatology for biologic eligibility
- Was Sie Ihren Kliniker fragen sollten
- What is my Hurley stage and HiSCR score, and have I been seen by an HS specialist?
- Have I tried first-line topical clindamycin, tetracyclines, or clindamycin-rifampicin combination?
- Am I a candidate for adalimumab or secukinumab? Have I been screened for biologic therapy?
- Have I been counseled on weight management, smoking cessation, and modifiable risk factors?
- Am I a candidate for surgical deroofing or wide excision of recalcitrant lesions?
- What evidence supports leech therapy in HS specifically?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Wann dringende medizinische Versorgung suchen
- Spreading redness, severe pain, fever, or pus drainage (worsening infection)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills (possible bacteremia)
- Hardness, dark discoloration, or crepitus in the affected area (necrotizing infection)
- Hives, throat tightness, or breathing difficulty
- Mental status changes or rapid heart rate (possible sepsis)
Was dies NICHT bedeutet
- This is not FDA-cleared for hidradenitis suppurativa.
- A single small case series does NOT establish efficacy on flare reduction versus proven biologics or antibiotics.
- Mechanism rationale (local immunomodulation) does NOT establish clinical efficacy.
- Leech therapy is NEVER applied on active draining lesions — that risks dangerous infection spread.
- Leech therapy is not a substitute for biologic therapy, antibiotics, or surgical management when indicated.
Sicherheits-Querverweise
Clinical Profile
- Category
- dermatological
- ICD-10
- L73.2
- Safety tier
- high
Evidence Summary
No controlled clinical trial or published case series demonstrating benefit of leech therapy in hidradenitis suppurativa exists; the only published report (Ferhatoglu et al., 2026) documents harm — a foreign-body granuloma complicated by lymphedema following leech therapy in an HS patient. Given this documented adverse-event signal and the infection risk inherent to HS lesions, leech therapy is not recommended, and any exploratory use would be investigational only, never on actively draining lesions. Standard management (topical clindamycin, oral antibiotics, adalimumab for moderate-severe disease, surgical excision for severe disease) remains primary.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Sharifi N et al. (2018), n=15
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active draining lesions or abscess
- Hurley stage III with extensive sinus tract disease
- Active immunomodulator-induced immunosuppression with neutropenia
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.